dismiss

Mark your calendars: the next Clean Sweep Live Auction will be on Thursday, January 25th--Click to view the full catalogue

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

 

Cardiology Homepage

Canadian resident pleads guilty in U.S. health care scam Sold device under false pretense of treating more than 200 diseases

FDA gives nod to MR-conditional labeling for Abbott ICD and CRT-D Labeling will reduce anxiety for patients who need scanning

Corindus and Mayo Clinic partner to study telestenting Can the CorPath GRX enable more patients to undergo PCI?

Alex Gorsky The American Heart Association names Johnson & Johnson Chairman & CEO as chairman of its CEO roundtable

Personalized medicine: The future of cardiology New technologies are improving cardiac care

Physicians halt life-threatening arrhythmias with stereotactic radiation First entirely noninvasive process proposed for treating ventricular tachycardia

Researchers develop new contrast agent for better MR detection of heart disease Reveals inflamed areas in resulting scans

Corindus announces first commercial installation of its CorPath GRX System outside U.S. Apex Heart Institute is the pioneer in India

Hitachi and Partners Connected Health assess readmission for heart failure with AI Assesses risk of readmission within the first 30 days following release

Researchers develop AI system to better detect risk of cancer in high-risk lesions Could reduce false positives and unnecessary surgeries

Transcatheter aortic valve replacement
Photo courtesy of Mayo Clinic

Edwards Lifesciences’ CENTERA valve demonstrates excellent clinical outcomes in new study

by Lauren Dubinsky , Senior Reporter
Treating transcatheter aortic valve replacement patients with Edwards Lifesciences’ CENTERA valve yields excellent clinical outcomes, according to a study presented today at EuroPCR 2017 in Paris.

The company announced that it was developing this repositionable, self-expanding valve in its December 2016 Investor Fact Sheet. It can be delivered through a low-profile 14-French delivery system that’s equipped with a motorized handle for stable valve deployment.

Story Continues Below Advertisement

CT, MRI, NM, SPECT/CT, PET & PET/CT service, refurbished systems and parts

Accelerate your ROI with our Black Diamond Certified refurbished systems. One year warranty - ISO 13485 Certified - FDA registered - Over 65k parts in inventory



"The Edwards CENTERA valve demonstrates extremely favorable early clinical safety and performance outcomes in the high surgical risk TAVR population," Dr. Didier Tchétché, of Clinique Pasteur in Toulouse, France, who presented the data, said in a statement.

"In addition to excellent patient outcomes, the valve also offers several unique features and an innovative tissue design, all of which simplify the procedure for clinicians,” he adds.

The 203 patients evaluated for the study had severe, symptomatic aortic stenosis and were too high-risk for open-heart surgery. A study published in Lancet found that more than one in eight people aged 75 and older have moderate or severe aortic stenosis (AS).

All of the patients were treated with the CENTERA valve via the transfemoral route, and 174 were under conscious sedation. After 30 days, 99 percent of the patients survived and 2.5 percent suffered a disabling stroke, which is considered a low rate.

Only 4.9 percent of the patients required a permanent pacemaker, which is the lowest rate ever reported in a multicenter trial for a self-expanding valve. In addition, there was a low .6 percent rate of moderate paravalvular leaks and no severe paravalvular leaks.

The patients were enrolled from 23 centers located in Europe, Australia and New Zealand. For the next five years, they will be monitored for additional research.

The CENTERA valve is still an investigational device, so it isn’t commercially available in any country to date. Edwards predicts that it will receive CE mark during the fourth quarter of this year.

Cardiology Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2018 DOTmed.com, Inc.
ALL RIGHTS RESERVED